Previous 10 | Next 10 |
Regulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwide TEVIMBRA is the cornerstone of BeiGene’s solid tumor portfolio, potentially pairing with more than 20 internal investigational assets as part of a broad, flex...
2023-09-11 03:06:49 ET Summary Zymeworks is a biotech company focused on developing therapies for hard-to-treat cancers. Its lead product, zanidatamab, has shown promising results in clinical trials and has been partnered with larger pharmaceutical companies. The company also ...
2023-09-04 07:46:14 ET Summary Zymeworks, a biotech firm, specializes in biotherapeutics for cancers, with primary product zanidatamab targeting HER2 and collaborations with BeiGene and Jazz Pharmaceuticals. Financially robust with $431.4M cash, revenue surged due to a Jazz deal, ...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11 th , 2023 with a fireside chat at 9:20 am ET. A live webcast of this e...
2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...
2023-08-17 17:06:53 ET More on BeiGene Sales Success Comes With Side Effects For Drug Maker BeiGene Heated Market For Dueling Blood Cancer Drugs Lands BeiGene In Court BeiGene Faces Patent Battle: Confronting Uncertainty In The Oncology Market BeiGene beats t...
2023-08-13 07:00:00 ET Summary BeiGene and Bristol-Myers Squibb have completed the breakup of their partnership, with BeiGene regaining shares worth $340 million. Gracell Biotechnologies raised $100 million in a private placement to support the development of its CAR-T therapies. ...
2023-08-10 04:53:00 ET Summary The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs. Global sales of BeiGene’s anti-tumor drug zanubrutinib more than doubled to $308 million (2.22 bi...
2023-08-07 17:44:22 ET Summary On July 20, Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. However, those results were overshadowed by a federal judge's decision to dismiss a JNJ subsidiary's bankruptcy fili...
2023-08-02 06:20:50 ET BeiGene press release ( NASDAQ: BGNE ): Q2 GAAP EPS of -$0.28 beats by $3.25 . Revenue of $595.26M (+74.3% Y/Y) beats by $79.9M . Global sales of BRUKINSA totaled $308 million in the quarter, a 139% increase from the prior-year period and...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...